nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadopentetate dimeglumine—PGD—Methotrexate—testicular cancer	0.753	1	CbGbCtD
Gadopentetate dimeglumine—Rash—Bleomycin—testicular cancer	0.000264	0.00107	CcSEcCtD
Gadopentetate dimeglumine—Pain—Cisplatin—testicular cancer	0.000264	0.00107	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Bleomycin—testicular cancer	0.000264	0.00107	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Ifosfamide—testicular cancer	0.000264	0.00107	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Methotrexate—testicular cancer	0.000261	0.00106	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Methotrexate—testicular cancer	0.000258	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Pollakiuria—Epirubicin—testicular cancer	0.000257	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Ifosfamide—testicular cancer	0.000257	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Methotrexate—testicular cancer	0.000254	0.00103	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Cisplatin—testicular cancer	0.000254	0.00103	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Etoposide—testicular cancer	0.000254	0.00103	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Ifosfamide—testicular cancer	0.000253	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Etoposide—testicular cancer	0.000252	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Etoposide—testicular cancer	0.000251	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Angina pectoris—Doxorubicin—testicular cancer	0.000251	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Methotrexate—testicular cancer	0.000251	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Bleomycin—testicular cancer	0.000249	0.00101	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Epirubicin—testicular cancer	0.000248	0.00101	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Dactinomycin—testicular cancer	0.000248	0.001	CcSEcCtD
Gadopentetate dimeglumine—Rash—Dactinomycin—testicular cancer	0.000246	0.000996	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Etoposide—testicular cancer	0.000246	0.000994	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Ifosfamide—testicular cancer	0.000245	0.000991	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Epirubicin—testicular cancer	0.000244	0.000988	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000244	0.000987	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Cisplatin—testicular cancer	0.000244	0.000987	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Etoposide—testicular cancer	0.000244	0.000986	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Etoposide—testicular cancer	0.000242	0.000978	CcSEcCtD
Gadopentetate dimeglumine—Pain—Etoposide—testicular cancer	0.000242	0.000978	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Epirubicin—testicular cancer	0.000241	0.000977	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Epirubicin—testicular cancer	0.000238	0.000964	CcSEcCtD
Gadopentetate dimeglumine—Pollakiuria—Doxorubicin—testicular cancer	0.000238	0.000964	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Ifosfamide—testicular cancer	0.000237	0.000958	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Methotrexate—testicular cancer	0.000235	0.000952	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000235	0.000951	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Methotrexate—testicular cancer	0.000234	0.000945	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Etoposide—testicular cancer	0.000233	0.000942	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Dactinomycin—testicular cancer	0.000232	0.000939	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Etoposide—testicular cancer	0.000231	0.000935	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Doxorubicin—testicular cancer	0.00023	0.00093	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Methotrexate—testicular cancer	0.00023	0.000929	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Ifosfamide—testicular cancer	0.000227	0.000921	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Cisplatin—testicular cancer	0.000227	0.00092	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Epirubicin—testicular cancer	0.000227	0.000919	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Doxorubicin—testicular cancer	0.000226	0.000914	CcSEcCtD
Gadopentetate dimeglumine—Rash—Ifosfamide—testicular cancer	0.000226	0.000913	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Ifosfamide—testicular cancer	0.000225	0.000912	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Methotrexate—testicular cancer	0.000225	0.000912	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Etoposide—testicular cancer	0.000224	0.000909	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Epirubicin—testicular cancer	0.000223	0.000905	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Etoposide—testicular cancer	0.000223	0.000904	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Etoposide—testicular cancer	0.000223	0.000904	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Doxorubicin—testicular cancer	0.000223	0.000904	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Methotrexate—testicular cancer	0.000223	0.000901	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Methotrexate—testicular cancer	0.000222	0.000899	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Cisplatin—testicular cancer	0.000221	0.000896	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Methotrexate—testicular cancer	0.000221	0.000895	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Doxorubicin—testicular cancer	0.00022	0.000892	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Epirubicin—testicular cancer	0.00022	0.000891	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Epirubicin—testicular cancer	0.00022	0.000889	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Epirubicin—testicular cancer	0.000219	0.000887	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Epirubicin—testicular cancer	0.000219	0.000885	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000217	0.00088	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Methotrexate—testicular cancer	0.000216	0.000875	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Methotrexate—testicular cancer	0.000215	0.000871	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Epirubicin—testicular cancer	0.000215	0.00087	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Methotrexate—testicular cancer	0.000215	0.000869	CcSEcCtD
Gadopentetate dimeglumine—Chills—Methotrexate—testicular cancer	0.000214	0.000865	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Ifosfamide—testicular cancer	0.000212	0.00086	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Cisplatin—testicular cancer	0.000211	0.000854	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Epirubicin—testicular cancer	0.000211	0.000853	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Doxorubicin—testicular cancer	0.00021	0.00085	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Methotrexate—testicular cancer	0.000209	0.000845	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Epirubicin—testicular cancer	0.000208	0.000843	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Etoposide—testicular cancer	0.000208	0.000843	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Epirubicin—testicular cancer	0.000208	0.000841	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Methotrexate—testicular cancer	0.000207	0.000839	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Epirubicin—testicular cancer	0.000207	0.000837	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Epirubicin—testicular cancer	0.000207	0.000837	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Doxorubicin—testicular cancer	0.000207	0.000837	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000204	0.000825	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Doxorubicin—testicular cancer	0.000203	0.000822	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Methotrexate—testicular cancer	0.000203	0.000822	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Etoposide—testicular cancer	0.000203	0.000821	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000203	0.00082	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Epirubicin—testicular cancer	0.000202	0.000819	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Doxorubicin—testicular cancer	0.000202	0.000818	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Epirubicin—testicular cancer	0.000201	0.000815	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Epirubicin—testicular cancer	0.000201	0.000813	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Methotrexate—testicular cancer	0.000201	0.000812	CcSEcCtD
Gadopentetate dimeglumine—Chills—Epirubicin—testicular cancer	0.0002	0.00081	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Etoposide—testicular cancer	0.0002	0.000809	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Epirubicin—testicular cancer	0.000199	0.000806	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Doxorubicin—testicular cancer	0.000199	0.000805	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Cisplatin—testicular cancer	0.000196	0.000794	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Epirubicin—testicular cancer	0.000195	0.000791	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Doxorubicin—testicular cancer	0.000195	0.000789	CcSEcCtD
Gadopentetate dimeglumine—Rash—Cisplatin—testicular cancer	0.000194	0.000787	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Cisplatin—testicular cancer	0.000194	0.000786	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Epirubicin—testicular cancer	0.000194	0.000786	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Etoposide—testicular cancer	0.000193	0.000783	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Doxorubicin—testicular cancer	0.000193	0.00078	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Doxorubicin—testicular cancer	0.000192	0.000778	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Doxorubicin—testicular cancer	0.000191	0.000775	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Doxorubicin—testicular cancer	0.000191	0.000775	CcSEcCtD
Gadopentetate dimeglumine—Tension—Epirubicin—testicular cancer	0.00019	0.000771	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Epirubicin—testicular cancer	0.00019	0.000769	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Epirubicin—testicular cancer	0.000188	0.00076	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Doxorubicin—testicular cancer	0.000187	0.000758	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Methotrexate—testicular cancer	0.000187	0.000757	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Etoposide—testicular cancer	0.000187	0.000756	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Doxorubicin—testicular cancer	0.000186	0.000754	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000186	0.000752	CcSEcCtD
Gadopentetate dimeglumine—Chills—Doxorubicin—testicular cancer	0.000185	0.000749	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Doxorubicin—testicular cancer	0.000184	0.000746	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Cisplatin—testicular cancer	0.000183	0.000742	CcSEcCtD
Gadopentetate dimeglumine—Cough—Methotrexate—testicular cancer	0.000181	0.000732	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Doxorubicin—testicular cancer	0.000181	0.000731	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Methotrexate—testicular cancer	0.00018	0.000727	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Etoposide—testicular cancer	0.00018	0.000727	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Doxorubicin—testicular cancer	0.00018	0.000727	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Epirubicin—testicular cancer	0.000178	0.000722	CcSEcCtD
Gadopentetate dimeglumine—Rash—Etoposide—testicular cancer	0.000178	0.000721	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Etoposide—testicular cancer	0.000178	0.00072	CcSEcCtD
Gadopentetate dimeglumine—Headache—Etoposide—testicular cancer	0.000177	0.000716	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Methotrexate—testicular cancer	0.000177	0.000715	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Methotrexate—testicular cancer	0.000177	0.000715	CcSEcCtD
Gadopentetate dimeglumine—Tension—Doxorubicin—testicular cancer	0.000176	0.000713	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Doxorubicin—testicular cancer	0.000176	0.000712	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000175	0.00071	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Epirubicin—testicular cancer	0.000175	0.000708	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Epirubicin—testicular cancer	0.000174	0.000704	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Doxorubicin—testicular cancer	0.000174	0.000703	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Methotrexate—testicular cancer	0.000171	0.000691	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Epirubicin—testicular cancer	0.000171	0.00069	CcSEcCtD
Gadopentetate dimeglumine—Cough—Epirubicin—testicular cancer	0.000169	0.000685	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Methotrexate—testicular cancer	0.000169	0.000685	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Epirubicin—testicular cancer	0.000168	0.000681	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Etoposide—testicular cancer	0.000168	0.000679	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Epirubicin—testicular cancer	0.000168	0.000678	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Methotrexate—testicular cancer	0.000166	0.000672	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Epirubicin—testicular cancer	0.000165	0.000669	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Epirubicin—testicular cancer	0.000165	0.000669	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Doxorubicin—testicular cancer	0.000165	0.000668	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Epirubicin—testicular cancer	0.000165	0.000666	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Methotrexate—testicular cancer	0.000164	0.000665	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000164	0.000664	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Methotrexate—testicular cancer	0.000164	0.000662	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Doxorubicin—testicular cancer	0.000162	0.000655	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Epirubicin—testicular cancer	0.000162	0.000654	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Methotrexate—testicular cancer	0.000161	0.000653	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Doxorubicin—testicular cancer	0.000161	0.000652	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Epirubicin—testicular cancer	0.00016	0.000646	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Epirubicin—testicular cancer	0.000158	0.000641	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Methotrexate—testicular cancer	0.000158	0.00064	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Doxorubicin—testicular cancer	0.000158	0.000639	CcSEcCtD
Gadopentetate dimeglumine—Cough—Doxorubicin—testicular cancer	0.000157	0.000634	CcSEcCtD
Gadopentetate dimeglumine—Shock—Epirubicin—testicular cancer	0.000156	0.000631	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Doxorubicin—testicular cancer	0.000156	0.00063	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Epirubicin—testicular cancer	0.000155	0.000629	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Doxorubicin—testicular cancer	0.000155	0.000628	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Epirubicin—testicular cancer	0.000155	0.000626	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000154	0.000624	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Epirubicin—testicular cancer	0.000154	0.000623	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Epirubicin—testicular cancer	0.000153	0.00062	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Doxorubicin—testicular cancer	0.000153	0.000619	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Doxorubicin—testicular cancer	0.000153	0.000619	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Doxorubicin—testicular cancer	0.000152	0.000617	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Methotrexate—testicular cancer	0.000152	0.000615	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000152	0.000615	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Epirubicin—testicular cancer	0.000151	0.000611	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Methotrexate—testicular cancer	0.000151	0.000611	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Methotrexate—testicular cancer	0.00015	0.000609	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Doxorubicin—testicular cancer	0.00015	0.000605	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Epirubicin—testicular cancer	0.000148	0.000599	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Doxorubicin—testicular cancer	0.000148	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Methotrexate—testicular cancer	0.000147	0.000596	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000147	0.000593	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000146	0.000591	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Methotrexate—testicular cancer	0.000146	0.000591	CcSEcCtD
Gadopentetate dimeglumine—Pain—Methotrexate—testicular cancer	0.000145	0.000586	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000144	0.000584	CcSEcCtD
Gadopentetate dimeglumine—Shock—Doxorubicin—testicular cancer	0.000144	0.000584	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Doxorubicin—testicular cancer	0.000144	0.000582	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Doxorubicin—testicular cancer	0.000143	0.000579	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Doxorubicin—testicular cancer	0.000142	0.000576	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Epirubicin—testicular cancer	0.000142	0.000576	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000142	0.000573	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Epirubicin—testicular cancer	0.000141	0.000572	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Epirubicin—testicular cancer	0.000141	0.00057	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Doxorubicin—testicular cancer	0.00014	0.000565	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Methotrexate—testicular cancer	0.000139	0.000565	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000138	0.00056	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Epirubicin—testicular cancer	0.000138	0.000557	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Doxorubicin—testicular cancer	0.000137	0.000554	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000137	0.000553	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Epirubicin—testicular cancer	0.000137	0.000553	CcSEcCtD
Gadopentetate dimeglumine—Pain—Epirubicin—testicular cancer	0.000135	0.000548	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Epirubicin—testicular cancer	0.000135	0.000548	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Methotrexate—testicular cancer	0.000134	0.000544	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Methotrexate—testicular cancer	0.000134	0.000542	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Methotrexate—testicular cancer	0.000134	0.000542	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000134	0.00054	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Doxorubicin—testicular cancer	0.000132	0.000533	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Doxorubicin—testicular cancer	0.000131	0.000529	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Epirubicin—testicular cancer	0.000131	0.000528	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Doxorubicin—testicular cancer	0.00013	0.000527	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Epirubicin—testicular cancer	0.00013	0.000524	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Doxorubicin—testicular cancer	0.000127	0.000516	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000127	0.000512	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Doxorubicin—testicular cancer	0.000126	0.000511	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Epirubicin—testicular cancer	0.000126	0.000509	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Doxorubicin—testicular cancer	0.000125	0.000507	CcSEcCtD
Gadopentetate dimeglumine—Pain—Doxorubicin—testicular cancer	0.000125	0.000507	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Epirubicin—testicular cancer	0.000125	0.000507	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Epirubicin—testicular cancer	0.000125	0.000507	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Methotrexate—testicular cancer	0.000125	0.000505	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Methotrexate—testicular cancer	0.000121	0.000491	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Doxorubicin—testicular cancer	0.000121	0.000489	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00012	0.000485	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Methotrexate—testicular cancer	0.00012	0.000485	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Epirubicin—testicular cancer	0.000117	0.000472	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Doxorubicin—testicular cancer	0.000116	0.000471	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Doxorubicin—testicular cancer	0.000116	0.000469	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Doxorubicin—testicular cancer	0.000116	0.000469	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Methotrexate—testicular cancer	0.000116	0.000469	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Epirubicin—testicular cancer	0.000114	0.00046	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Epirubicin—testicular cancer	0.000112	0.000454	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Methotrexate—testicular cancer	0.000112	0.000453	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Epirubicin—testicular cancer	0.000108	0.000439	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Doxorubicin—testicular cancer	0.000108	0.000437	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Methotrexate—testicular cancer	0.000108	0.000436	CcSEcCtD
Gadopentetate dimeglumine—Rash—Methotrexate—testicular cancer	0.000107	0.000432	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Methotrexate—testicular cancer	0.000107	0.000432	CcSEcCtD
Gadopentetate dimeglumine—Headache—Methotrexate—testicular cancer	0.000106	0.000429	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Doxorubicin—testicular cancer	0.000105	0.000426	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Epirubicin—testicular cancer	0.000105	0.000424	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Doxorubicin—testicular cancer	0.000104	0.00042	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Epirubicin—testicular cancer	0.000101	0.000408	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Methotrexate—testicular cancer	0.000101	0.000407	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Doxorubicin—testicular cancer	0.0001	0.000406	CcSEcCtD
Gadopentetate dimeglumine—Rash—Epirubicin—testicular cancer	9.99e-05	0.000404	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Epirubicin—testicular cancer	9.98e-05	0.000404	CcSEcCtD
Gadopentetate dimeglumine—Headache—Epirubicin—testicular cancer	9.92e-05	0.000402	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Doxorubicin—testicular cancer	9.69e-05	0.000392	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Epirubicin—testicular cancer	9.41e-05	0.000381	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Doxorubicin—testicular cancer	9.32e-05	0.000377	CcSEcCtD
Gadopentetate dimeglumine—Rash—Doxorubicin—testicular cancer	9.24e-05	0.000374	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Doxorubicin—testicular cancer	9.23e-05	0.000374	CcSEcCtD
Gadopentetate dimeglumine—Headache—Doxorubicin—testicular cancer	9.18e-05	0.000372	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Doxorubicin—testicular cancer	8.7e-05	0.000352	CcSEcCtD
